数据链接：
官方服务：
资源简介：
R is the ratio of tumor burden before and after the treatment ().
应用场景：
创建时间：
2020-10-05
相关数据集
Proteomic Characterization of the Gastric Cancer Response to Chemo- and Targeted therapies Reveals Axis of the Immune and Metabolic Pathways
Herein, we set out to investigate the responses to first-line therapies (DOS, XELOX, and anti-HER2-based therapies) for GC through a comprehensive proteomic analysis. We constructed a GC cohort that c
Mendeley Data90
DLBCL-reminiscent MyD88- or CARD11-mutant aggressive B-cell lymphomas exhibit strong pro-senescent and immune-evasive phenotypes [part2]
Aberrant B-cell receptor (BCR)/NF-kB signaling activity is a prominent feature of diffuse large B-cell lymphoma (DLBCL), particularly of, but not restricted to the activated B-cell (ABC) subtype. Recu
NIAID Data Ecosystem70
Table_2_A pyroptosis-associated gene risk model for predicting the prognosis of triple-negative breast cancer.xls
BackgroundPyroptosis is a novel identified form of inflammatory cell death that is important in the development and progression of various diseases, including malignancies. However, the relationship b
NIAID Data Ecosystem20
Multi-Omics Biomarkers of Response to Immunotherapy in Combination with Epigenetic Modulators
Epigenetic immunomodulation by association of guadecitabine with ipilimumab (NIBIT-M4 Phase Ib trial, NCT02608437) has been shown to be safe and tolerable in advanced melanoma and to have significant
NIAID Data Ecosystem80
RNA-Seq of MC38 tumors in responder and non-responder CCF1 lines
In this study we investigated variation in responsiveness to anti-PD-1 using a model where we implanted the MC38 colorectal cancer cell line in genetically diverse host mice. To quantify differences i
Figshare2024-08-12 更新50
